Baxter to enhance renal therapy portfolio with Gambro acquisition
Baxter has entered into a definitive agreement to acquire privately-held Gambro, based in Lund, Sweden, for total consideration of SKr 26.5 billion (approximately US$4.0 billion). Gambro is a global medical technology company focused on developing, manufacturing and supplying dialysis products and therapies for patients with acute or chronic kidney disease. The acquisition will give Baxter a comprehensive dialysis product portfolio, complementing its existing home dialysis offerings.
Gambro's portfolio in the traditional chronic care segment consists of haemodynamic devices including advanced monitors, dialysers, bloodlines, cyclers and dialysis systems. The company's in-centre haemodialysis devices include the Artis and the AK 96 systems. In the acute care segment, which includes continuous renal replacement therapy and treatment for fluid overload, among others, Gambro offers the Prismaflex system used for the treatment of critically ill patients with acute kidney injury.